It was learned that on December 5, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as “Fosun Pharmaceuticalâ€) announced that its holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (hereinafter referred to as “Fosun Pharmaceutical Industryâ€) ) with Revance Therapeutics, Inc. (hereinafter referred to as “Revanceâ€) signing the license agreement, Fosun Pharma industry will have exclusive use, import and sales in the region (ie mainland China, Hong Kong and Macao Special Administrative Region) and in the field (including cosmetic indications and treatment indications) And other commercialization (excluding manufacture) of the injectable drug RT002 (hereinafter referred to as "RT002" or "product") containing Daxibotulinumtoxin type A botulinum toxin. Under the agreement, Fosun Pharma should pay Revance up to US$88 million in licensing fees and pay the corresponding sales milestones. Founded in 1999, Revance is a biopharmaceutical company specializing in the development, production and commercialization of new botulinum toxin products for a variety of cosmetic and therapeutic indications. RT002 is a long-acting neuromodulator developed at the clinical research stage based on Revance's proprietary technology platform. Its pharmaceutically active ingredient is Daxibotulinumtoxin botulinum toxin type A, which contains no blood-derived substances or animal-derived proteins and is capable of maintaining two-year stability without refrigeration. Based on the results of pre-clinical and clinical studies that have been completed, RT002 can be used for cosmetic indications such as elimination of moderate to severe eyebrow lines; and for treatment indications such as cervical dystonia. Up to now, there are no products containing Daxibotulinumtoxin type A botulinum toxin in China (excluding Hong Kong, Macao and Taiwan). According to the latest data of IQVIA CHPA (provided by IQVIA, the world's leading provider of professional information and strategic consulting services for the pharmaceutical and health industry), the sales volume of Botox type A for injection in China was approximately RMB 234 million in 2017. yuan. “Fosun Pharmaceutical is a leading medical and health industry group in China. It has rich product line and therapeutic adaptability research, as well as professional management ability and management experience in medical beauty equipment and treatment. Fosun Pharma is our realization of RT002 in China business. "The ideal partner for the company," said Mr. Dan Browne, President and CEO of Revance. "China's medical beauty equipment market is booming. We look forward to working with Fosun Pharma to open RT002 clinical trials, registration approval and business in China. Process." Wu Yifang, President and CEO of Fosun Pharma, said: “We are very honored to cooperate with Revance to bring more efficient, safer and better quality neuromodulation products to domestic consumers and patients. At the same time, this cooperation will be beneficial. Our product line in the field of medical beauty continues to actively support and promote the development and layout in the field of medical beauty, providing more choices for the unmet needs of the market." We provide wide range of herb tea cut, like echinacea tea, nettle leaf tea, dandelion root tea, valerian root tea and red raspberry leaf tea. We can provide blend herbal tea according to formula of customer and we also provide formula according to needs of customers. As one stop shop store of natural ingredients, tea bags like pyramid tea bag and string tea bag can be processed too. Private label is acceptable. Herb Tea Cut,Echinacea Tea,Nettle Leaf Tea,Dandelion Root YT(Xi'an) Biochem Co., Ltd. , https://www.ytherblifes.com
Continue to promote the layout of the medical beauty field, Fosun Pharma industry and the botulinum toxin company Revance signed a license agreement